Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial

MLA

Chris A Rogers, et al. “Cost-Effectiveness of Ranibizumab and Bevacizumab for Age-Related Macular Degeneration: 2-Year Findings from the IVAN Randomised Trial.” BMJ Open, vol. 4, no. 7, July 2014. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f26e76ecaf75873b336965f43bab444f&authtype=sso&custid=ns315887.

APA

Chris A Rogers, Susan M. Downes, Helen Dakin, James Raftery, Usha Chakravarthy, Andrew J. Lotery, Simon P. Harding, Sarah Wordsworth, Giselle Abangma, & Barnaby C Reeves. (2014). Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial. BMJ Open, 4(7).

Chicago

Chris A Rogers, Susan M. Downes, Helen Dakin, James Raftery, Usha Chakravarthy, Andrew J. Lotery, Simon P. Harding, Sarah Wordsworth, Giselle Abangma, and Barnaby C Reeves. 2014. “Cost-Effectiveness of Ranibizumab and Bevacizumab for Age-Related Macular Degeneration: 2-Year Findings from the IVAN Randomised Trial.” BMJ Open 4 (7). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....f26e76ecaf75873b336965f43bab444f&authtype=sso&custid=ns315887.